3-(morpholine-4-carbonyl)cyclobutan-1-one | 917828-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-(morpholine-4-carbonyl)cyclobutan-1-one
• 英文别名: 3-(morpholin-4-ylcarbonyl)cyclobutanone；3-(Morpholin-4-ylcarbonyl)cyclobutanone
• CAS: 917828-08-1
• 化学式: C₉H₁₃NO₃
• 分子量: 183.207
• InChiKey: YRPDFABHWOVYJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(morpholine-4-carbonyl)cyclobutan-1-one 在 lithium aluminium tetrahydride 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 3.25h， 生成 4-({trans-3-[3-methoxy-4-(pyrrolidin-1-ylmethyl)phenoxy]cyclobutyl}methyl)morpholine
  参考文献：
  名称：

  WO2006/136924

  摘要：

  公开号：
• 作为产物：
  描述：

  吗啉 在 N,N'-羰基二咪唑 作用下， 反应 4.08h， 以81%的产率得到3-(morpholine-4-carbonyl)cyclobutan-1-one
  参考文献：
  名称：

  WO2006/136924

  摘要：

  公开号：

文献信息

• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Wager T. Travis

  公开号：US20080096955A1

  公开（公告）日：2008-04-24

  This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种式I的化合物，如本文所定义，或其药学上可接受的盐；包含式I化合物的制药组合物；制备式I化合物的方法；一种治疗通过拮抗组胺H3受体可治疗的紊乱或病症的方法，该方法包括向需要此类治疗的哺乳动物投与上述式I化合物；以及治疗所选组中的紊乱或病症的方法，所选组包括抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低运动和酸性分泌，该方法包括向需要此类治疗的哺乳动物投与上述式I化合物。
• Histamine-3 receptor antagonists
  申请人：Pfizer Inc.

  公开号：US08158673B2

  公开（公告）日：2012-04-17

  This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种公式I的化合物，如本文所定义，或其药学上可接受的盐；包含公式I化合物的制药组合物；制备公式I化合物的方法；一种治疗通过拮抗组胺H3受体可治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物；以及一种治疗从以下疾病或症状中选择的疾病或症状的方法，包括抑郁症、情感障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低动力和酸性分泌，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物。
• Histamine-3 Receptor Antagonists
  申请人：Wager Travis T.

  公开号：US20120220568A1

  公开（公告）日：2012-08-30

  This invention is directed to a compound of formula I, wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 and n are as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition such as depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种式子为I的化合物，其中R1、R2、R4、R5、R6、R7、R8和n如此定义，或其药学上可接受的盐；一种含有式I化合物的制药组合物，一种制备式I化合物的方法，一种治疗抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏诱发的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、消化道疾病、胃肠道高低动力和酸性分泌物疾病的方法，该方法包括向需要此类治疗的哺乳动物给予上述式I化合物。
• <i>syn</i>-Selective Difunctionalization of Bicyclobutanes Enabled by Photoredox-Mediated C–S σ-Bond Scission
  作者：Huamin Wang、Johannes E. Erchinger、Madina Lenz、Subhabrata Dutta、Constantin G. Daniliuc、Frank Glorius

  DOI：10.1021/jacs.3c08512

  日期：2023.11.1

  regio- and syn-selectivity is disclosed. C–S σ-bond cleavage of partially unsaturated sulfur-containing bifunctional reagents in an overall strain-release-driven process enables the thio-alkynylation, -alkenylation, and -allylation of BCBs under mild conditions and demonstrates the generality of this protocol. Mechanistic studies suggest that the intermediacy of cyclic distonic radical cations might be

  鉴于环状框架在分子支架和药物发现中的重要性，在合成化学中精确锻造和操纵环系统是很有趣的。在这一领域，在简单的反应条件下精确非对映控制的密集取代环丁烷的分子间合成仍然是一个挑战。在此，公开了在高区域选择性和顺式选择性下双环[1.1.0]丁烷（BCB）双官能化的光氧化还原策略。在整个应变释放驱动过程中，部分不饱和含硫双功能试剂的 C-S σ 键裂解使得 BCB 在温和条件下发生硫代炔基化、烯基化和烯丙基化，并证明了该协议的通用性。机理研究表明，环状双张力自由基阳离子的中介作用可能是 C-S σ 键有效断裂和非对映选择性起源的关键。
• Enolate addition to bicyclobutanes enables expedient access to 2-oxo-bicyclohexane scaffolds
  作者：Kyla J. Woelk、Kushal Dhake、Nathan D. Schley、David C. Leitch

  DOI：10.1039/d3cc04234k

  日期：——

  We report the synthesis of 2-oxo-bicyclo[2.1.1]hexanes (2-oxo-BCHs) from bicyclobutanes (BCBs) and readily available enolate precursors. Glycine-derived enolates directly give protected 2-oxo-3-amino-BCH derivatives that can be further functionalized. Arylacetate derivatives are also suitable enolate precursors, giving 2-oxo-3-aryl-BCH scaffolds from readily available starting materials.

  我们报道了从双环丁烷（BCB）和容易获得的烯醇化物前体合成2-氧代-双环[2.1.1]己烷（2-氧代-BCH）。甘氨酸衍生的烯醇化物直接产生受保护的 2-oxo-3-amino-BCH 衍生物，可以进一步官能化。芳基乙酸酯衍生物也是合适的烯醇化物前体，从容易获得的起始材料得到2-氧代-3-芳基-BCH支架。